Specific active immunochemotherapy in lung cancer: a survival study

Area of Science:

• Oncology
• Immunology

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Early-stage diagnosis (Stages I and II) offers the best prognosis but requires effective treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of chemotherapy, immunization, and immunochemotherapy in patients with early-stage lung cancer.
• To determine if patient immunization impacts survival rates in conjunction with standard treatments.

Main Methods:

• A randomized clinical trial involving 55 patients diagnosed with Stage I or II lung cancer.
• Comparison of survival rates between immunized and non-immunized patient groups receiving chemotherapy or immunochemotherapy.

Main Results:

• Significantly improved survival rates were observed in the immunized patient groups (P = 0.001).
• The study highlights a positive correlation between specific cancer antigen reactivity and treatment outcomes.

Conclusions:

• Immunization, particularly in combination with chemotherapy (immunochemotherapy), demonstrates a significant survival benefit for early-stage lung cancer patients.
• Further research into cancer antigen-specific immunotherapy is warranted for lung carcinoma treatment.